---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-022600"
form_type: "8-K"
ticker: "XTNT"
cik: "0001453593"
company_name: "Xtant Medical Holdings, Inc."
filed_at: "2026-05-13T11:05:34+00:00"
generated_at: "2026-05-13T11:12:40.666998+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Xtant Medical Q1 2026 net loss $3.1M; revenue falls to $20.9M, raises 2026 guidance to $101-105M

## Summary
- Q1 2026 revenue $20.9M vs $32.9M YoY; decline driven by asset sale to Companion Spine and license revenue ceasing.
- Net loss of $3.1M vs net income of $58K in Q1 2025; non-GAAP adjusted EBITDA loss $1.6M vs +$3.0M.
- Full-year 2026 revenue guidance raised to $101-105M from $95-99M reflecting HEMOBLAST incremental revenue.
- Entered exclusive US distribution for Dilon Technologies' HEMOBLAST Bellows; hired approx. 20-person sales team.
- Reduced total indebtedness by $13.3M; cash $12.2M, availability under revolver $11.8M as of March 31, 2026.

## SEC filing metadata
- accession: 0001493152-26-022600
- form_type: 8-K
- ticker: XTNT
- cik: 0001453593
- company_name: Xtant Medical Holdings, Inc.
- filed_at: 2026-05-13T11:05:34+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1453593/000149315226022600/0001493152-26-022600-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1453593/000149315226022600/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-022600
- JSON: https://secwatch.observer/filing/0001493152-26-022600.json
- Plain text: https://secwatch.observer/filing/0001493152-26-022600.txt

## Key facts
- Earnings Releases
  Xtant Medical Holdings, Inc. reported first quarter ended March 31, 2026 results: revenue $20.9 million, net income net loss was $3.1 million. Guidance raised.
  - Period: first quarter ended March 31, 2026
  - Revenue: $20.9 million
  - Net income: net loss was $3.1 million
  - Guidance: raised
  - Result: reported results
  source text: conditions, today reported financial and operating results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Highlights ● Generated total revenue of $20.9 million for the first quarter of 2026, as compared to $32.9 million for the first quarter of 2025. The decline in revenue relates primarily to the sale of assets and businesses to
  evidence_url: https://www.sec.gov/Archives/edgar/data/1453593/000149315226022600/0001493152-26-022600-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.